The treatment of urinary stone disease is one of the most urgent and complex issue in modern urology. Citrate is one of the most important natural urinary inhibitors of stone formation. In this regard, the drugs containing citrate sodium and potassium are being actively used.
Aim: to assess the efficiency and safety of Uryklar, dietary supplements.
Material and methods: A total of 57 patients with proximal ureteric stones were included in the study (intervention group (n=30) and control group (n=27)). After stenting all patients received antispasmoic, anti-inflammatory and antimicrobial therapy. In the intervention group Uryklar was additionally administered (405 mg), 1 capsule TID for 1 month. All patients were undergone to extracorporeal shock-wave lithotripsy with subsequent removing of the stent. In all cases multiplanar CT was done before and 28 days after initiation of drug therapy for determination of stone size, contour and density. 10 days after stent removal the symptoms and stone-free rate were assessed using US, plain X-ray and intravenous urography, blood count, urinalysis, biochemical blood analysis.
Results. In patients receiving Uryklar, there was a significant reduction of stone size during the observation, up to complete dissolution.

Keywords: Uryklar, urinary stone disease, citrate therapy